Associate Professor of Medical Oncology, Cleveland Cl College of Medicine/Case West Res
Oncology
Dr. David M. Peereboom, MD
|
|
Give Review
David Peereboom is an expert in the field of Oncology. He went to Virginia Commonwealth University School of Medicine. He over the years received 4 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification" and "Northern Ohio Live". Doctor David M. Peereboom, MD is also published. He has 75 publications published. The lastest publication: "Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.' Doctor David M. Peereboom, MD is registered with Medicare and accepts Medicare payments.
Publications
- Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicen...
- Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast Cancer patients: a prospective study.
- Recurrent or refractory primary central Nervous lymphoma: therapeutic considerations.
- Primary central Nervous system lymphoma in the elderly: the cleveland clinic experience.
- Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy.
- NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
- Ogilvie's Syndrome During Chemotherapy With High-Dose Methotrexate for Primary CNS Lymphoma.
- Clinical Trial Design in Brain Metastasis: Approaches for a Unique Patient Population.
- Flow cytometry as a diagnostic tool in Lymphomatous or leukemic meningitis: Ready for prime time?
- Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article.
- Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases.
- Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade Gliomas.
- A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
- Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
- Blood-Brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.
- Maculopathy as a complication of blood-Brain barrier disruption in patients with central nervous system lymphoma.
- Chemotherapy delivery issues in central Nervous system malignancy: a reality check.
- Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme.
- Chemotherapy in Brain metastases.
- Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme.
- Primary central Nervous system germ cell tumors.
- Gliomatosis cerebri: treatment results with radiotherapy alone.
- SWOG-9510: evaluation of topotecan in hormone refractory prostate Cancer: a Southwest Oncology Group study.
- Brain metastases from Bladder carcinoma: presentation, treatment and survival.
- Role of tyrosine kinase inhibitors in the management of high-grade Gliomas.
- Targeted delivery in primary and metastatic Brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium.
- It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology.
- Chemotherapy in newly diagnosed primary central Nervous system lymphoma.
- A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade Gliomas.
- Intraocular rituximab.
- Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade Gliomas.
- Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.
- Irinotecan and bevacizumab in progressive primary Brain tumors, an evaluation of efficacy and safety.
- Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant Gliomas.
- Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendroGliomas and mixed anaplastic oligoastrocytomas: RTO...
- Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
- Isolated secondary CNS relapse in a case of stage I diffuse large B-cell Lymphoma.
- The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making.
- Delivery of chemotherapy and antibodies across the blood-Brain barrier and the role of chemoprotection, in primary and metastatic Brain tumors: report of the Eleventh ...
- Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b.
- Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung Cancer.
- Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate Cancer (HRPC).
- New frontiers in translational research in neuro-oncology and the blood-Brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting.
- Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate Cancer.
- Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
- Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.
- Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study.
- Delayed appearance of carbon granulomas of the scalp after use of carbon fiber pins for refixation of a stereotactic head frame. Case report.
- Successful re-treatment with taxol after major hypersensitivity reactions.
- From serendipity to design: the evolution of drug development in oncology.
- Mature results from a phase II trial of accelerated induction chemoradiotherapy and surgery for poor prognosis stage III non-small-cell lung Cancer.
- Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate Cancer.
- Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
- Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal Carcinoma.
- Eikenella corrodens cervical osteomyelitis: case report.
- Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung Cancer.
- Evaluation of docetaxel in previously untreated extensive-stage small cell lung Cancer: a Southwest Oncology Group phase II trial.
- Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell Carcinoma.
- Second-generation interferons for Cancer: clinical targets.
- A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal Cancer.
- Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell Carcinoma: clinical results and immunologic correlates of response.
- Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast Cancer.
- Signal transduction abnormalities in T lymphocytes from patients with advanced renal Carcinoma: clinical relevance and effects of cytokine therapy.
- Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate Cancer.
- Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell Carcinoma.
- Cytotoxic effects of topotecan combined with various antiCancer agents in human Cancer cell lines.
- Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid Tumors.
- Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
- Topoisomerases in human leukemia.
- Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal Cancer: toxicity and pharmacokinetics.
- Locally advanced prostate Cancer.
- A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell Carcinoma.
- Current medical treatment of glioblastoma.
- Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central Nervous system lymphoma.
Schools
Virginia Commonwealth University School Of Medicine
Johns Hopkins Hospital
University Hospital Of Cleveland
Johns Hopkins
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Coventry Health America PPO
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Medical Mutual of Ohio POS
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Northern Ohio Live
Education
-
Johns Hopkins University -
Case Western Reserve University - University Hospitals -
Virginia Commonwealth University School of Medicine
Hospital
-
Cleveland Clinic
Drug Facts
| NPI NUMBER | 1548262512 | |
| NPPES Provider LastName | PEEREBOOM | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 441950001 | |
| NPPES Provider State | OH | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 337.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 3.26 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1548262512 |
| Last Name Of The Provider | PEEREBOOM |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Robert Dreicer, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan B. LeGrand, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy P. Spiro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deepa Jagadeesh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nathan A. Pennell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shaveta Vinayak, MD
This Doctor is OpenDoctor Recommended.
|